April is National Minority Health Month, a time to recognize and raise awareness of health disparities that affect racial and ethnic minorities.
The biopharmaceutical industry believes innovation is for everyone. However, some populations may face heightened challenges in benefiting from such innovation given systematic and longstanding issues largely driven by community-based inequities. Poor access to care and low medication adherence contribute to these disparities. For example, according to the Department of Health and Human Services Office of Minority Health:
- Minorities have higher rates of chronic disease, including asthma, diabetes and heart attacks;
- African American and Hispanic patients with cardiovascular disease are 10-40% less likely than white patients to receive secondary prevention therapies;
- Nonwhite patients are 53% more likely than white patients to be non-adherent to their treatment regimes.
Sickle cell disease (SCD) is another example of a condition that disproportionately affects racial minorities, with 1 in 13 African Americans born with the sickle cell trait. SCD is life-threatening, due to potential complications from blocked blood vessels, which can include stroke, difficulty breathing, pulmonary hypertension and other organ damage.
The biopharmaceutical industry is working to alleviate some of the costs associated with SCD and improve the quality of life for patients of all races and ethnicities living with the disease. According to a new report, 17 new treatments are in development for the disease, all of which are in clinical trials or awaiting U.S. Food and Drug Administration (FDA) review. These innovative treatments are exploring new ways to use established medicines and cutting-edge technologies such as RNA interference, gene-edited stem cell therapy and gene therapy.
By leveraging the power of the entire health care system and listening to each patient’s unique needs, we can work together to put patient care first and elevate prevention, innovative treatments and cures for all.
The FDA’s Office of Minority Health provides further information resources here.
Courtney Christian
Courtney Christian is a Deputy Vice President of Policy and Research at PhRMA focusing on state-based reforms impacting health insurance, prescription drug coverage in public health programs and on health equity. Prior to joining PhRMA, she worked at the Black Women’s Health Imperative as Director of Policy and Advocacy, and on Capitol Hill for a number of years in a series of roles, including as Legislative Director. Courtney is a Florida State football fan (and alum), aspiring chef, and mom to an energetic preschooler.
Courtney Christian
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Report: More than 1,300 medicines and vaccines in development to help fight cancer
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Nearly 140 medicines in development to treat mental illness
New report finds 15 new oncology therapies launched last year
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Event: New era of medicine comes to Capitol Hill
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
Disrupting Alzheimer's
Aspen Spotlight Health: Discussing the forefront of innovation
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Rare Disease Day: Unmet need inspires innovation
ICYMI: Why 2017 medicine approvals matter
New report and event examine the new era of vaccines
A new era in cancer
How biopharmaceutical collaboration is driving a new era of medicine
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Finding cures for incurable diseases
New report portrays flourishing pipeline
Going boldly together: New advancements and new anniversaries
Examining the brain in The New Era of Medicine
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Minority health matters
New Era of Medicine
Minority health matters
Minority health matters